# Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis.

- **DOI:** [10.1111/ene.70602](https://doi.org/10.1111/ene.70602)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** Paired CSF data identify KFLC decline during natalizumab as a promising response signal, but uncontrolled confounding prevents validated predictive interpretation.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1111%2Fene.70602

## Key claims

1. Natalizumab appears to reduce intrathecal KFLC synthesis, and a decline in KFLC index may reflect effective suppression of CNS humoral immunity.
   - Support: Supported
   - Type: Primary finding
   - Basis: paired pre-post evidence supports the decline, though nonrandomized treatment and absent controls limit causal attribution
   - Location: Abstract, Conclusions
2. A decrease greater than −9 perfectly distinguished patients maintaining NEDA-3 status from those with evidence of disease activity.
   - Support: Tentative
   - Type: Secondary
   - Basis: the cutoff was selected in-sample from a 22-person subgroup with only five EDA-3 events
   - Location: Discussion, predictive-performance paragraph; Results, Figure 2B
3. a decrease in KFLC index is associated with favorable treatment response and reduced progression independent of inflammatory activity.
   - Support: Tentative
   - Type: Secondary
   - Basis: the temporally ordered association remains unadjusted for baseline prognostic differences and treatment selection
   - Location: Discussion, final paragraph

## Strengths

- **Prospective paired biomarker sampling design** CSF and serum were collected before treatment and again at a fixed 12-month interval, with standardized processing and no more than one freeze–thaw cycle. This supports consistent within-patient measurement.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Analyses of intrathecal immunoglobulin synthesis
- **Biomarker change precedes most outcomes** ΔKFLC was defined over months 0–12, while NEDA-3 and PIRMA+ events were assessed during months 12–60; the Results state that only one event for each endpoint coincided with 12-month sampling.
  - Dimension: methodological rigour
  - Location: Materials and Methods, Evaluation of treatment response; Results, NEDA-3 and PIRMA+ sections
- **Relevant extension of KFLC evidence** The study links longitudinal KFLC change with treatment-response endpoints, complementing prior studies described as cross-sectional, variably timed, or not connected to clinical response.
  - Dimension: contribution
  - Location: Introduction, final paragraph; Discussion, prior-work paragraphs

## Limitations

- **Confounding remains uncontrolled throughout analyses** Treatment allocation was nonrandom, NTZ patients differed in baseline EDSS and contrast-enhancing lesions, and no multivariable adjustment, matching, or stratified sensitivity analysis addressed these differences.
  - Dimension: methodological rigour
  - Location: Results, Demographic and clinical data; Discussion, limitations paragraphs
- **Perfect discrimination is not validated** The NEDA-3 AUC of 1.0 and cutoff of −9 were derived in the same 22-person NTZ subgroup, with only five EDA-3 events and wide sensitivity and specificity intervals.
  - Dimension: contribution
  - Location: Results, Predictive value of ΔKFLC index; Figure 2B
- **Headline wording exceeds exploratory evidence** The abstract says ΔKFLC “predicted outcomes” and that DMF produced “no meaningful change,” although the analyses were exploratory and DMF CSF KFLC declined significantly. The direct NTZ–DMF difference was not tested.
  - Dimension: reporting
  - Location: Abstract, Results; Results, Changes in KFLC index by treatment; Discussion, limitations paragraphs

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "More patients starting NTZ had CELs at baseline compared with those starting DMF (54.2% vs. 38.5%, p = 0.023)." (Results, Demographic and clinical data at baseline and follow-up) vs "At baseline, 26 patients were assigned to DMF and 22 to NTZ." (Results, Demographic and clinical data at baseline and follow-up). With 22 NTZ patients, 54.2% implies 11.924 patients, whereas 12/22 rounds to 54.5%, establishing an incompatible percentage and denominator but not identifying the actual counts needed to recompute the reported between-group p-value. → Effect on result unclear
- **Reporting and transparency:** Clean. No specific reporting or research-conduct concern remains after screening the supplied concerns.
  - Conflict of interest: declared · Ethics approval: declared · Data availability: declared · Code availability: not stated
- **Reference integrity:** Clean
  - 25 references in manuscript
  - 25 of 25 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
